<DOC>
	<DOCNO>NCT00541853</DOCNO>
	<brief_summary>This study examine safety efficacy calcium channel blocker ( CCB ) treatment hypertension Autosomal Dominant Polycystic Kidney Disease ( ADPKD ) patient . Angiotensin receptor blocker ( ARB ) show kidney protect effect patient renal disease include ADPKD , glomerulonephritis diabetic nephropathy . In case whose blood pressure normalize ARB alone , CCB select additionally . Recent research suggest genetic calcium channel disorder responsible progression ADPKD . It examine clinically CCB treatment harmful effect patient ADPKD . This study examine safety Cilnidipine ( CCB ) ADPKD patient whose blood pressure control 130/85 mmHg Candesartan ( ARB ) alone .</brief_summary>
	<brief_title>CCB Safety Study Treatment Hypertension ADPKD</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Cilnidipine</mesh_term>
	<criteria>ADPKD patient . Blood pressure measure outpatient set 130/85 mmHg . Age 20 60 year old . Plasma creatinine le 2.0mg man 1.5mg woman . Patients give informed consent . Patients severe cardiovascular hepatic disorder . Patients complication central nervous vascular disorder . Women breast feeding female childbearing potential use acceptable contraceptive method . Patients currently engage experimental protocol . Patients intracranial aneurysma . Patients must use diuretic . Allergic patient Candesartan Cilnidipine . Patients whose hypertension control medication protocol .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin-2 Receptor Blocker</keyword>
	<keyword>Calcium Channel Blocker</keyword>
	<keyword>Kidney Volume</keyword>
</DOC>